

This article discusses the effect of punitive damages in drug product liability cases and provides suggestions for substantive and procedural reforms. The threat and imposition of punitive damages has distorted pharmaceutical research and development, and has restricted, and in some cases eliminated, the availability of important medicines. Because they lack sufficient standards to guide them, juries are free to impose substantial punitive damage awards even for conduct that was approved in advance by the Food and Drug Administration (FDA).